426 related articles for article (PubMed ID: 32871345)
21. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
23. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
24. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
25. PROTACs: New method to degrade transcription regulating proteins.
Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
[TBL] [Abstract][Full Text] [Related]
26. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
27. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
Kiely-Collins H; Winter GE; Bernardes GJL
Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
[TBL] [Abstract][Full Text] [Related]
28. PROTACs: A novel strategy for cancer therapy.
Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
[TBL] [Abstract][Full Text] [Related]
29. Chemically induced degradation of epigenetic targets.
Kabir M; Yu X; Kaniskan HÜ; Jin J
Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
[TBL] [Abstract][Full Text] [Related]
30. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
31. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
32. PROTACs to address the challenges facing small molecule inhibitors.
Martín-Acosta P; Xiao X
Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
[TBL] [Abstract][Full Text] [Related]
33. Controlling PROTACs with Light.
Verma S; Manna D
ChemMedChem; 2020 Jul; 15(14):1258-1261. PubMed ID: 32558301
[TBL] [Abstract][Full Text] [Related]
34. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
35. Bifunctional Molecules beyond PROTACs.
Conway SJ
J Med Chem; 2020 Mar; 63(6):2802-2806. PubMed ID: 32157887
[TBL] [Abstract][Full Text] [Related]
36. A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
Shanmugasundaram K; Shao P; Chen H; Campos B; McHardy SF; Luo T; Rao H
J Biol Chem; 2019 Oct; 294(41):15172-15175. PubMed ID: 31511327
[TBL] [Abstract][Full Text] [Related]
37. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications.
Heitel P
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677746
[TBL] [Abstract][Full Text] [Related]
38. Small-Molecule PROTACS: New Approaches to Protein Degradation.
Toure M; Crews CM
Angew Chem Int Ed Engl; 2016 Feb; 55(6):1966-73. PubMed ID: 26756721
[TBL] [Abstract][Full Text] [Related]
39. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
40. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.
Edmondson SD; Yang B; Fallan C
Bioorg Med Chem Lett; 2019 Jul; 29(13):1555-1564. PubMed ID: 31047748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
